Patent details
300941
Product Name:
Canakinumab
The time of generation of the report may vary depending on the number of the selected files and the pages of each file. If the generation of the consolidated PDF file takes long, you may reduce the number of selected files and proceed with the generation of the PDF in batches.
Ok
Cancel
You have not selected any documents
Ok
Basic Information
Publication number:
300941
Type:
Certificate
SPC Type:
Medical
Basic Patent Number:
EP2848258
Status:
Refused Art. 10 of the EC Regulations
Application number:
300941
Procedural language:
Dutch
First Applicant Residence Country:
Switzerland (CH)
Marketing Authorization
Marketing Authorization Number:
C(2017)1412
Marketing Authorization Type:
EEA
Marketing Authorization Date:
23/02/2017
Marketing Authorization Country:
European Union (EU)
Dates
Filing date:
08/06/2018
First Marketing Authorization date:
23/02/2017
Grant date:
Activation date:
Lapsed By Non Payment Annual Fee Date:
Renunciation Date:
NullificationDate:
Registration date:
13/06/2018
SPC/SPC Extension Expiration Date:
Lapsed By Expiration Date:
Withdrawal date:
Revocation Date:
Invalidity Date:
Withdrawal Market Authorization Date:
Refusal Date:
21/12/2020
Applicant/holder
From:
08/06/2018
Name:
Novartis AG
Address:
Lichtstrasse 35, 4056 BASEL, Switzerland (CH)
Agent
Name:
ir. M.F.J.M. Ketelaars c.s.
From:
08/06/2018
Address:
NLO
Postbus 29720, 2502 LS, Den Haag, Netherlands (NL)
To:
Publication
Bulletin
1
Bulletin Heading:
VRV
Journal edition number:
52/20
Publication date:
23/12/2020
Description:
Lapse or annulment
2
Bulletin Heading:
SPC
Journal edition number:
26/18
Publication date:
20/06/2018
Description:
Applications and granted Supplementary Protection Certificates (or the extensions of the Supplementary Protection Certificates)
Filing date
Document type
Document Description
Number of pages
File Type
21/12/2020
Outgoing Correspondence
Decision refusal
3
PDF
/6/8/4/1/8/0800281486/docs/300941_8_385504l527a.pdf
14/10/2020
Outgoing Correspondence
Letter to applicant
1
PDF
/6/8/4/1/8/0800281486/docs/300941_5_372442l173.pdf
13/10/2020
Incoming Correspondence Paper
Accompanying letter incoming document
1
PDF
/6/8/4/1/8/0800281486/docs/300941_4_incomingcorrespondencepaper20210310032418735.pdf
14/07/2020
Outgoing Correspondence
Letter to applicant
3
PDF
/6/8/4/1/8/0800281486/docs/300941_6_353991l173.pdf
13/06/2018
Outgoing Correspondence
Confirmation receipt request
1
PDF
/6/8/4/1/8/0800281486/docs/300941_3_212444l174.pdf
08/06/2018
SPC Documents
Annex SPC
10
PDF
/6/8/4/1/8/0800281486/docs/300941_0_supplprotectioncertificate20200526050947792.pdf
08/06/2018
SPC Documents
Accompanying letter SPC
4
PDF
/6/8/4/1/8/0800281486/docs/300941_1_supplprotectioncertificate20200922010814038.pdf
08/06/2018
SPC Documents
Marketing Authorization SPC
3
PDF
/6/8/4/1/8/0800281486/docs/300941_2_supplprotectioncertificate20180613105233252.pdf
08/06/2018
Application Form
First filed application form
2
PDF
/6/8/4/1/8/0800281486/docs/300941_7_applicationform20180613105233091.pdf
08/06/2018
SPC Documents
Summary of the characteristics of the product
78
PDF
/6/8/4/1/8/0800281486/docs/300941_9_supplprotectioncertificate20180613105233386.pdf
08/06/2018
SPC Documents
Annex SPC
66
PDF
/6/8/4/1/8/0800281486/docs/300941_10_supplprotectioncertificate20180613105233532.pdf
08/06/2018
SPC Documents
Annex SPC
4
PDF
/6/8/4/1/8/0800281486/docs/300941_11_supplprotectioncertificate20180613105233446.pdf